Neurodegeneration in streptozotocin-induced diabetic rats is attenuated by treatment with resveratrol

Neuroendocrinology

Volumn 98, Issue 2, 2013, Pages 116-127

  Jing, Yu Hong ^a,c   Chen, Kuan Hsing ^a,b   Kuo, Pei Ching ^a   Pao, Chia Chi ^a   Chen, Jan Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c LANZHOU UNIVERSITY   (China)

Author keywords

Astrocyte; Diabetic encephalopathy; Neurodegeneration; Resveratrol

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CHOLESTEROL; FRUCTOSAMINE; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD VESSEL PERMEABILITY; BRAIN TISSUE; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ENCEPHALOPATHY; DIABETIC NEUROPATHY; DRUG MECHANISM; HIPPOCAMPUS; HYPERGLYCEMIA; MALE; MITOCHONDRION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN MITOCHONDRION; BRAIN NERVE CELL; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOLOGY; METABOLIC PARAMETERS; NEUROPROTECTION; OUTCOME ASSESSMENT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; ASTROCYTES; BLOOD-BRAIN BARRIER; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; HIPPOCAMPUS; MALE; NERVE DEGENERATION; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; STREPTOZOCIN;

EID: 84886417630     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000350435     Document Type: Article

References (72)

1. Biessels GJ, Bravenboer B, Gispen WH: Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. Eur J Pharmacol 2004; 490: 1-4.
2. Strotmeyer ES, de Rekeneire N, Schwartz AV, Faulkner KA, Resnick HE, Goodpaster BH, Shorr RI, Vinik AI, Harris TB, Newman AB: The relationship of reduced peripheral nerve function and diabetes with physical performance in older white and black adults: the Health, Aging, and Body Composition (Health ABC) study. Diab Care 2008; 31: 1767-1772.
3. Launer LJ: Diabetes and brain aging: epide-miologic evidence. Curr Diab Rep 2005; 5:59-63.
4. Reske-Nielsen E, Lundbæk K, Rafaelsen O: Pathological changes in the central and peripheral nervous system of young long-term diabetics. Diabetologia 1966; 1:233-241.
5. Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH: Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res 1998; 800:125-135.
6. Li L, Holscher C: Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007; 56:384-402.
7. Sima AA, Kamiya H, Li ZG: Insulin, C-pep-tide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol 2004; 490:187-197.
8. Manschot SM, Biessels GJ, Cameron NE, Cotter MA, Kamal A, Kappelle LJ, Gispen WH: Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-di-abetic rats. Brain Res 2003; 966:274-282.
9. Mastrocola R, Restivo F, Vercellinatto I, Dan-ni O, Brignardello E, Aragno M, Boccuzzi G: Oxidative and nitrosative stress in brain mitochondria of diabetic rats. J Endocrinol 2005; 187:37-44.
10. Zochodne DW, Ramji N, Toth C: Neuronal targeting in diabetes mellitus: a story of sensory neurons and motor neurons. Neurosci-entist 2008; 14:311-318.
11. Araque A: Astrocytes process synaptic information. Neuron Glia Biol 2008; 4:3-10.
12. Brown AM, Ransom BR: Astrocyte glycogen and brain energy metabolism. Glia 2007; 55: 1263-1271.
13. Escartin C, Bonvento G: Targeted activation of astrocytes: a potential neuroprotective strategy. Mol Neurobiol 2008; 38:231-241.
14. Nehlig A, Coles JA: Cellular pathways of energy metabolism in the brain: is glucose used by neurons or astrocytes? Glia 2007; 55:1238-1250.
15. Schummers J, Yu H, Sur M: Tuned responses of astrocytes and their influence on hemody-namic signals in the visual cortex. Science 2008; 320:1638-1643.
16. Wolf F, Kirchhoff F: Neuroscience. Imaging astrocyte activity. Science 2008; 320:1597-1599.
17. Daulhac L, Mallet C, Courteix C, Etienne M, Duroux E, Privat AM, Eschalier A, Fialip J: Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol 2006; 70:1246-1254.
18. Takano T, Oberheim N, Cotrina ML, Neder-gaard M: Astrocytes and ischemic injury. Stroke 2009; 40:S8-S12.
19. Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC: Inflammation mediates varying effects in neurogenesis: relevance to the patho-genesis of brain injury and neurodegenerative disorders. J Neurochem 2009; 108:1343-1359.
20. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5:493-506.
21. Pervaiz S: Resveratrol: from grapevines to mammalian biology. FASEB J 2003; 17:1975-1985.
22. Chen JK, Chow SE: Antioxidants and myo-cardial ischemia: reperfusion injuries. Chang Gung Med J 2005; 28:369-377.
23. Sinha K, Chaudhary G, Gupta YK: Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 2002; 71:655-665.
24. Chen KH, Cheng ML, Jing YH, Chiu DT, Shiao MS, Chen JK: Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2011; 301:E853-E863.
25. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ: Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardio-vasc Res 2000; 47:549-555.
26. Ray PS, Maulik G, Cordis GA, Bertelli AA, Bertelli A, Das DK: The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Rad Biol Med 1999; 27:160-169.
27. Huang SS, Tsai MC, Chih CL, Hung LM, Tsai SK: Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci 2001; 69:1057-1065.
28. Tsai SK, Hung LM, Fu YT, Cheng H, Nien MW, Liu HY, Zhang FB, Huang SS: Resvera-trol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J Vasc Surg 2007; 46:346-353.
29. Virgili M, Contestabile A: Partial neuropro-tection of in vivo excitotoxic brain damage by chronic administration of the red wine anti-oxidant agent, trans-resveratrol in rats. Neu-rosci Lett 2000; 281:123-126.
30. Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Sener M, Kocak A, Yologlu S: Neuroprotec-tion by resveratrol against traumatic brain injury in rats. Mol Cell Biochem 2007; 294:137-144.
31. Dasgupta B, Milbrandt J: Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007; 104:7217-7222.
32. Sharma M, Briyal S, Gupta YK: Effect of alpha lipoic acid, melatonin and trans resveratrol on intracerebroventricular streptozotocin induced spatial memory deficit in rats. Ind J Physiol Pharmacol 2005; 49:395-402.
33. Sharma M, Gupta YK: Chronic treatment with trans resveratrol prevents intracerebro-ventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002; 71:2489-2498.
34. Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, Turkoz Y, Yologlu S: Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 2007; 14:256-260.
35. Alvarez EO, Beauquis J, Revsin Y, Banzan AM, Roig P, De Nicola AF, Saravia F: Cognitive dysfunction and hippocampal changes in experimental type 1 diabetes. Behav Brain Res 2009; 198:224-230.
36. Su HC, Hung LM, Chen JK: Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2006; 290:E1339-E1346.
37. Schmued LC, Stowers CC, Scallet AC, Xu L: Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 2005; 1035:24-31.
38. Paxinos G, Watson C: The Rat Brain in Ste-reotaxic Coordinates, ed 5. Amsterdam, Elsevier Academic Press, 2004.
39. Wirenfeldt M, Dalmau I, Finsen B: Estimation of absolute microglial cell numbers in mouse fascia dentata using unbiased and efficient stereological cell counting principles. Glia 2003; 44:129-139.
40. Yang SZ, Zhang LM, Huang YL, Sun FY: Distribution of Flk-1 and Flt-1 receptors in neonatal and adult rat brains. Anat Rec A Discov Mol Cell Evol Biol 2003; 274:851-856.
41. Ribaudo R, Gilman M, Kingston RE, Choc-zynski P, Sacchi N: Preparation of RNA from tissues and cells; in Coligan JE, et al (eds): Current Protocols in Immunology 2001, chap 10, unit 10, 11.
42. 1 receptor antagonist. Regul Peptides 2005; 124:221-224.
43. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH: Ageing and diabetes: implications for brain function. Eur J Pharmacol 2002; 441:1-14.
44. Johnson DR, Sherry CL, York JM, Freund GG: Acute hypoxia, diabetes, and neuroim-mune dysregulation: converging mechanisms in the brain. Neuroscientist 2008; 14:235-239.
45. Leonard BE: Inflammation, depression and dementia: are they connected? Neurochem Res 2007; 32:1749-1756.
46. Weinstock M, Shoham S: Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cy-tochrome oxidase activity. J Neural Transm 2004; 111:347-366.
47. Griffiths MR, Gasque P, Neal JW: The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009; 68: 217-226.
48. Inoue K: The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther 2006; 109: 210-226.
49. Tekkök S, Kriz J, Padjen AL, Krnjevic K: Higher sensitivity of CA1 synapses to aglyce-mia in streptozotocin-diabetic rats is age-dependent. Brain Res 1998; 813:268-273.
50. Brands AM, Kessels RP, de Haan EH, Kap-pelle LJ, Biessels GJ: Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels. Eur J Pharmacol 2004; 490:159-168.
51. Satoh J, Yagihashi S, Toyota T: The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 2003; 4: 65-71.
52. de la Lastra CA, Villegas I: Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res 2005; 49:405-430.
53. Docherty JJ, Fu MM, Hah JM, Sweet TJ, Faith SA, Booth T: Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. Antiviral Res 2005; 67:155-162.
54. Migliore L, Coppede F: Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat Res 2009; 674:73-84.
55. Norata GD, Marchesi P, Passamonti S, Pirillo A, Violi F, Catapano AL: Anti-inflammatory and anti-atherogenic effects of cathechin, caf-feic acid and trans-resveratrol in apolipopro-tein E deficient mice. Atherosclerosis 2007; 191:265-271.
56. Sugimoto K, Yasujima M, Yagihashi S: Role of advanced glycation end products in diabetic neuropathy. Curr Pharmaceut Design 2008; 14:953-961.
57. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M: MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec (Hoboken) 2009; 292:1902-1913.
58. Whitmarsh AJ: Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim Biophys Acta 2007; 1773:1285-1298.
59. Huber JD: Diabetes, cognitive function, and the blood-brain barrier. Curr Pharmaceut Design 2008; 14:1594-1600.
60. Lorenzi M, Karam JH, McIlroy MB, Forsham PH: Increased growth hormone response to dopamine infusion in insulin-dependent diabetic subjects: indication of possible blood-brain barrier abnormality. J Clin Invest 1980; 65:146-153.
61. Antonetti DA, Barber AJ, Hollinger LA, Wol-pert EB, Gardner TW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonu-la occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274:23463-23467.
62. Fischer S, Clauss M, Wiesnet M, Renz D, Schaper W, Karliczek GF: Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am J Physiol 1999; 276:C812-C820.
63. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD: Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007; 50: 202-211.
64. Fischer S, Wobben M, Marti HH, Renz D, Schaper W: Hypoxia-induced hyperperme-ability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc Res 2002; 63:70-80.
65. Ceriello A: New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 2003; 26:1589-1596.
66. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-820.
67. Rolo AP, Palmeira CM: Diabetes and mito-chondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212:167-178.
68. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lo-pez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ra-maswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337-342.
69. Jornayvaz FR, Shulman GI: Regulation of mi-tochondrial biogenesis. Essays Biochem 2010; 47:69-84.
70. Venturini CD, Merlo S, Souto AA, Fernandes Mda C, Gomez R, Rhoden CR: Resveratrol and red wine function as antioxidants in the nervous system without cellular proliferative effects during experimental diabetes. Oxid Med Cell Longev 2010; 3:434-441.
71. Deng JY, Hsieh PS, Huang JP, Lu LS, Hung LM: Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and-independent pathways. Diabetes 2008; 57:1814-1823.
72. Schmatz R, Mazzanti CM, Spanevello R, Ste-fanello N, Gutierres J, Corrêa M, da Rosa MM, Rubin MA, Chitolina Schetinger MR, Morsch VM: Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol 2009; 610:42-48.